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MENINGOCOCCAL DISEASEoccurs with an inci-dence of 0.2 to 14 per100 000 population in in-
dustrialized countries.1 Effective vac-
cines based on capsular polysaccha-
rides for meningococcal serogroups A,
C, W-135, and Y are available,2 but sero-
group B capsular polysaccharide is an-
tigenically similar to human neural cell
glycopeptides containing polysialic acid
and poorly immunogenic in humans.
Serogroup B Neisseria meningitidis
(MenB) vaccines based on detergent-
extracted outer membrane vesicles
(OMVs) containing outer membrane
proteins, including porin protein A,For editorial comment see p 614.
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Context In theabsenceof aneffectivevaccine, serogroupBNeisseriameningitidis (MenB)
remains a major cause of invasive disease in early childhood in developed countries.
Objective To determine the immunogenicity and reactogenicity of a multicomponent
MenB vaccine (4CMenB) and routine infant vaccineswhen given either concomitantly or
separately.
Design, Setting, and Participants Phase 2b, multicenter, open-label, parallel-
group, randomized controlled study of 1885 infants enrolled at age 2 months from
August 2008 to July 2010 in Europe.
Intervention Participants were randomized 2:2:1:1 to receive (1) 4CMenB at 2, 4,
and 6 months with routine vaccines (7-valent pneumococcal and combined diphthe-
ria, tetanus, acellular pertussis, inactivated polio, hepatitis B, Haemophilus influenzae
type b vaccines); (2) 4CMenB at 2, 4, and 6 months and routine vaccines at 3, 5, and
7 months; (3) 4CMenB with routine vaccines at 2, 3, and 4 months; or (4) routine
vaccines alone at 2, 3, and 4 months.
MainOutcomeMeasures Percentage of participants with human complement se-
rum bactericidal activity (hSBA) titer of 1:5 or greater against 3 MenB strains specific
for vaccine antigens (NZ98/254, 44/76-SL, and 5/99).
Results After three 4CMenB vaccinations, 99% or more of infants developed hSBA
titers of 1:5 or greater against strains 44/76-SL and 5/99. For NZ98/254, this proportion
was 79% (95% CI, 75.2%-82.4%) for vaccination at 2, 4, and 6 months with routine
vaccines, 86.1% (95%CI, 82.9%-89.0%) for vaccination at 2, 4, and 6months without
routine vaccines, and81.7%(95%CI, 76.6%-86.2%) for vaccination at 2, 3, and4months
with routine vaccines. Responses to routine vaccines given with 4CMenB were noninfe-
rior to routine vaccines alone for all antigens, except for the responses to pertactin and
serotype 6B pneumococcal polysaccharide. Fever was seen following 26% (158/602) to
41% (247/607) of 4CMenB doses when administered alone, compared with 23% (69/
304) to 36% (109/306) after routine vaccines given alone and 51% (306/605) to 61%
(380/624) after 4CMenB and routine vaccines administered together.
Conclusion A 4CMenB vaccine is immunogenic against reference strains when ad-
ministered with routine vaccines at 2, 4, and 6 or at 2, 3, and 4 months of age, pro-
ducing minimal interference with the response to routine infant vaccinations.
Trial Registration clinicaltrials.gov Identifier: NCT00721396
JAMA. 2012;307(6):573-582 www.jama.com
©2012 American Medical Association. All rights reserved. JAMA, February 8, 2012—Vol 307, No. 6 573
Corrected on February 28, 2012
Downloaded From: http://jama.jamanetwork.com/ by a UNIEVERSITA DEGLI STUDI DI FIRENZE User  on 07/30/2012
proved effective in clinical trials and
controlled a clonal MenB outbreak in
New Zealand.3,4 However, the high
strain specificity of these vaccines lim-
its their usefulness, especially in in-
fants and young children.5,6
To develop a vaccine with broader
protection, novel antigens identified by
sequencing the MenB genome—
factor-H binding protein variant 1
(fHbp1), Neisserial adhesin A (NadA),
and Neisseria heparin binding antigen
(NHBA)—were combined with OMVs
from the New Zealand epidemic strain
NZ98/254 in a multicomponent sero-
group B meningococcal vaccine
(4CMenB).7 To facilitate manufacture
and enhance protein stability, fHbp1
and NHBA were combined with other
proteins identified during genome se-
quencing to create 2 fusion pro-
teins.8,9 Small studies in infants dem-
onstrated immunogenicity of 4CMenB
against reference strains.8,9
In this study we assessed the immu-
nogenicity and reactogenicity of
4CMenB in a large cohort of infants
when given in 2 different schedules, and
concomitantly or separately from rou-
tine vaccines.
METHODS
Study Participants and Trial Design
This phase 2b, open-label, parallel-
group, randomized controlled trial was
conducted between August 2008 and
July 2010 in Belgium (6 centers), United
Kingdom (4 centers), Czech Republic (4
centers), Germany (25 centers), Italy (5
centers), and Spain (16 centers). Ap-
propriate regulatory authorities in each
participating country granted approval
for the trial. Participants were healthy,
full-term, 2-month-old infants with a
birth weight of 2.5 kg or greater, whose
parent(s) or legal guardian(s) provided
written informed consent. In the United
Kingdom, participants were recruited by
information letters sent via National
Health Service child health computer da-
tabases; participants in other study cen-
ters were recruited through pediatric
hospitals or private practices. Exclu-
sion criteria were any history of menin-
gococcal infection or close contact with
someone experiencing meningococcal
disease; prior receipt of meningococcal
B or C vaccines or any of the nationally
recommended routine infant vaccines;
acute or chronic illness; known reac-
tions to vaccine components; known or
suspected immune disease or impair-
ment, including the administration of
steroids; receipt of antibiotics 6 days
prior to enrollment; receipt of blood
products; or planned receipt of non-
study vaccines. Investigator-defined op-
tions for race/ethnicity were chosen by
the participants’ parents for demo-
graphic description of the study popu-
lation.
Intervention
The 4CMenB vaccine consisted of 50
µg each of fHbp1, NadA, and NHBA fu-
sion proteins, 25 µg of detoxified OMV
from N meningitidis strain NZ98/254,
1.5 of mg aluminum hydroxide, and
histidine 10mM in 0.5 mL of water for
injection. Participants also received a
combined diphtheria, tetanus, acellu-
lar pertussis, inactivated polio, hepati-
tis B, and Haemophilus influenzae type
b vaccine (DTaP-HBV-IPV/Hib) (In-
fanrix Hexa; GlaxoSmithKline) and
7-valent pneumococcal glycoconju-
gate vaccine (PCV7) (Prevnar; Wyeth
Pharmaceuticals). These are referred to
as routine vaccines, although they do
not necessarily reflect the routine vac-
cines used in each study country.
The study design allowed assess-
ment of 3 primary 4CMenB sched-
ules: ages 2, 4, and 6 months, together
with routine infant vaccines (concomi-
tant); 2, 4, and 6 months, with routine
vaccines given separately at 3, 5, and 7
months (intercalated); and 2, 3, and 4
months, concomitantly with routine in-
fant vaccines (accelerated). A control
group received DTaP-HBV-IPV/Hib and
PCV7 only at 2, 3, and 4 months. These
immunization time points were cho-
sen to reflect schedules currently used
in different countries. All vaccines were
administered by intramuscular injec-
tion in the anterolateral thigh; 4CMenB
and routine vaccines given concomi-
tantly were administered in opposite
limbs.
Participants were randomized to the
4 vaccination groups in a 2:2:1:1 ratio
according to a centrally held random-
ization list (Biostatistics and Clinical
Data Management, Novartis) using a
fixed block size of 6. The unequal
allocation ratio was chosen to effi-
ciently assess primary as well as sec-
ondary objectives. This was an open-
label study; ie, study personnel and
parents both knew which vaccines were
being administered.
Immunology
Sera obtained before the first vaccina-
tion and 30 (−4/7) days after the third
dose of 4CMenB (or routine vaccines in
the control group) were shipped to the
Novartis Vaccines Serology Laboratory,
Marburg, Germany, for blinded immu-
nology assessments. Human comple-
ment serum bactericidal activity (hSBA)
was assessed against 3 target strains cho-
sen to determine the immunogenicity of
individual vaccine components—
strain 44/76-SL for fHBP1, strain 5/99 for
NadA, and strain NZ98/254 for OMV.
The hSBA was expressed as interpo-
lated titers according to reciprocal se-
rum dilutions yielding 50% or greater
killing of the target strain after 60 min-
utesof incubationcomparedwithgrowth
at time 0. An interpolated titer of 1:5 or
greater represented 95% confidence that
participants achieving this titer had a pro-
tective hSBA titer (1:4).10
Because no hSBA strain specific for
NHBA was available at the time of
analysis, antibodies to NHBA were mea-
sured by enzyme-linked immunosor-
bent assay and expressed as geometric
mean concentrations (GMCs).
Responses to routine vaccines were
determined for participants in the ac-
celerated and control groups only, ac-
cording to availability of serum, using
standard correlates of protection to in-
terpret responses. Geometric mean ti-
ters (GMTs) of hSBA, routine vaccine
antigen-specific IgG GMCs, and the be-
tween-group ratios of GMT and GMC
were calculated (with 2-sided 95% CIs)
using 2-way analysis of variance with
a factor for vaccine group and immu-
nization center.
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Safety
Parents recorded local injection site re-
actions (pain, erythema, swelling, and
induration) and systemic reactions (ie,
fever [axillary temperature 38°C],
change in eating habits, sleepiness, un-
usual crying, vomiting, diarrhea, irri-
tability, rash) for 7 days after each vac-
cination. Injection site pain was
classified by the parents as mild (mini-
mal discomfort when the child’s leg was
touched), moderate (obvious discom-
fort when the leg was touched), or se-
vere (pain on movement of the leg).
Erythema, induration, and swelling
were summarized by maximal sever-
ity (1-25 mm, 25-50 mm, and50 mm,
respectively).
Adverse event recording was en-
hanced by telephone contact in the
week after study vaccination. Safety fol-
low-ups were completed 6 months af-
ter the last dose of 4CMenB (and at age
10 months in the control group). All se-
rious adverse events reported during the
study were recorded. Determination of
the relationship between adverse events
and the study vaccine was made by a
study investigator’s judgment based on
temporal relationship and biological
plausibility criteria.
Statistics
The primary outcome was assessment
of percentages of participants with hSBA
titers of 1:5 or greater 1 month after im-
munization with 4CMenB in the con-
comitant and accelerated groups, vac-
cine response being sufficient if the
lower limit of the 2-sided 95% Clopper-
Pearson11 CI of this percentage was 70%
or greater for all 3 reference strains. In
addition, hSBA titers were log trans-
formed and their GMTs and 2-sided
95% CIs calculated. The prespecified
population for this analysis was the
modified intention-to-treat popula-
tion, including only those who re-
ceived a study vaccine and provided
evaluable serum samples before and af-
ter immunization.
The main secondary outcomes were
noninferiority of immune responses to
4CMenB and routine vaccines admin-
istered together compared with sepa-
rately. The percentage of 4CMenB re-
cipients achieving hSBA titers of 1:5 or
greater in the concomitant group, ob-
tained from a categorical linear model,
was considered noninferior to that in
the intercalated group if the lower lim-
its of the 95% CI for the differences in
these percentages (concomitant mi-
nus intercalated) was greater than
−10%.12 The same criteria were used to
determine noninferiority between the
control and accelerated groups for the
response to routine vaccines.
Additionally, a post hoc noninferior-
ity criterion for the geometric mean ra-
tios of 4CMenB response (intercalated di-
vided by concomitant) obtained from
analysis of variance adjusting for center
was defined as the lower limit of the 95%
CI being greater than 0.5 for all 3 strains.
For pertussis antigens, noninferiority of
the accelerated compared with the con-
trol group was achieved if the lower limit
of the 2-sided 95% CI for the ratio of the
antigen-specific IgG GMCs after vacci-
nation was greater than 0.67. All anti-
gen thresholds were chosen based on tra-
ditional use and acceptance by regulatory
authorities. Responses to antigens ad-
ministered at the same time were ana-
lyzed in a per-protocol population, ie,
those who received all designated vac-
cines on time and provided sera within
the scheduled window (23-55 days post
vaccination) and who received no pro-
hibited medications (systemic antibiot-
ics or systemic/high-dose inhaled
corticosteroids).
Modified intention-to-treat analysis
was performed as per-randomized
group; the per-protocol population was
analyzed as per-immunization course
received.
A post hoc analysis was performed
that used all available data and in-
cluded imputed values to replace miss-
ing data.13 Each missing value was re-
placed with a set of plausible values that
represent the uncertainty about the cor-
rect values to impute. Variables in-
cluded in the imputation model were
actual vaccine administered, center, age,
birth weight, weight, height, sex, race,
hSBA titers for strains 44/76-SL, 5/99,
and NZ98/254 (at baseline and follow-
ing the third dose), and IgG GMC
against NHBA using the adjusted Wald
test proposed by Agresti and Coull.14
The sample size calculation for the pri-
mary outcome was determined using a
simulation approach to estimate that 300
participants in the accelerated group
would yield 95% power to demonstrate
that the lower limit of the 2-sided 95%
CI for the true percentage of partici-
pants with hSBA titer of 1:5 or greater
was 70% or greater. A sample size of 600
in the concomitant and intercalated
groups was calculated to provide 87%
power to demonstrate noninferiority in
response rates for all 3 MenB strains (as-
suming only 80% provided evaluable
sera, response rates to 4CMenB given to-
gether with routine immunizations were
similar to those in previously published
studies,8,9 and that response rates to
4CMenB given without routine immu-
nizations were 2% higher for each strain).
Individuals who received at least 1
dose of vaccine and provided postbase-
line safety data were included in the
safety analyses, for which results were
reported descriptively with no formal
statistical analyses.
Statistical analysis was performed
using SAS version 9.1.
RESULTS
A total of 1885 participants were en-
rolled (United Kingdom, 561; Italy, 371;
Germany, 317; Czech Republic, 283;
Belgium, 248; Spain, 105), of whom
1810 (96%) completed the study. Of
these, 1636 were included in the modi-
fied intention-to-treat immunogenic-
ity analysis (FIGURE 1) and 1599 in the
per-protocol immunogenicity analy-
sis. Median age at enrollment was 68.7
days for all groups, 48.3% to 53.4% of
each group were boys, and 93.1% of all
participants were white.
Immunogenicity
Primary Outcome. After immuniza-
tion with 4CMenB and routine vac-
cines together at either 2, 4, and 6 or
2, 3, and 4-months, 99% or more of par-
ticipants had hSBA titers of 1:5 or
greater for strains 44/76-SL and 5/99 in
the modified intention-to-treat analy-
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sis (FIGURE 2 and TABLE 1). For strain
NZ98/254, percentages were 79.0%
(417/528 [95% CI, 75.2% to 82.4%])
and 81.7% (219/268 [95% CI, 76.6% to
86.2%]) following concomitant or ac-
celerated schedules. Lower limits of the
95% CIs were greater than 70% for all
3 tested reference strains, thereby meet-
ing the predefined criteria of a suffi-
cient immune response. Results from
multiple imputation analysis were simi-
lar (Table 1).
Secondary Outcomes. The differ-
ence in the percentage of participants
with hSBA titers of 1:5 or greater in
the concomitant group minus the
intercalated group met the prespeci-
fied noninferiority criterion for
44/76-SL and 5/99 but not NZ98/254
(−7.1% [95% CI, −11.7% to −2.6%])
(Table 1). Although the lower limit of
the 95% CI for the geometric mean
concomitant to intercalated hSBA
ratios were all above 0.5, thus meeting
Figure 1. Flowchart of the Modified Intention-to-Treat (MITT) Population
552 Included in primary immunogenicity
analysis
544 Included in primary immunogenicity
analysis
278 Included in primary immunogenicity
analysis
262 Included in primary immunogenicity
analysis
625 Received intercalated schedule
as randomized
4 Received concomitant schedule
2 Received accelerated schedule
1 Received routine schedule
310 Received routine schedule
as randomized
1 Received concomitant schedule
2 Received intercalated schedule
1 Received accelerated schedule
315 Received accelerated schedule
as randomized
1 Received concomitant schedule
1 Received intercalated schedule
621 Received concomitant schedule
as randomized
1 Received routine schedule
632 Randomized to receive
intercalated schedule
317 Randomized to receive
accelerated schedule
314 Randomized to receive
routine schedule (control)
622 Randomized to receive
concomitant schedule
52 Excluded
43 No serum or no results (before
or after immunization)
7 Withdrawn (withdrew consent)
2 Lost to follow-up
88 Excluded
55 No serum or no results (before
or after immunization)
27 Withdrawn
5 Lost to follow-up
1 Not vaccinated
15 Withdrew consent
7 Adverse event
4 Protocol deviation
1 Inappropriate enrollment
39 Excluded
31 No serum or no results (before
or after immunization)
7 Withdrawn
1 Lost to follow-up
3 Withdrew consent
2 Adverse event
1 Protocol deviation
1 Administrative reason
70 Excluded
45 No serum or no results (before
or after immunization)
18 Withdrawn
5 Lost to follow-up
2 Not vaccinated
9 Withdrew consent
4 Adverse event
2 Protocol deviation
3 Administrative reason
1885 Participants randomized
See “Methods” for definitions of groups. The number of infants approached, assessed for eligibility, and primarily excluded is unknown. Six-month follow-up in the
safety population was completed by 597 participants in the concomitant group, 599 in the intercalated group, 309 in the accelerated group, and 305 in the routine
(control) group. This chart does not show the flow of participants for the per-protocol population (used for calculations of Neisseria heparin binding antigen enzyme-
linked immunosorbent assay data and response to concomitant vaccines).
Figure 2. Reverse Cumulative Distribution of hSBA Titers at 1 Month After the Third 4CMenB Vaccination, by Meningococcal Strain (MITT
Population)
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See “Methods” for definitions of groups. Numbers of participants in each group are as reported in Figure 1. Blue vertical lines indicate reference for hSBA titers of
1:5 or greater. 4CMenB indicates multicomponent serogroup B meningococcal vaccine; hSBA, human complement serum bactericidal activity; MITT, modified
intention-to-treat.
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the prespecified noninferiority crite-
rion, it is notable that the upper limit
of the 95% CI for these ratios were all
less than 1 (TABLE 2).
The geometric mean ratios (con-
comitant divided by accelerated) of
hSBA titers were similar for strains 44/
76-SL and NZ98/254 (confidence in-
tervals crossing 1) but higher for strain
5/99 (1.61 [95% CI, 1.41 to 1.84]). IgG
GMCs against NHBA 1 month after the
third 4CMenB vaccination were 4342
(95% CI, 4067-4635) when 4CMenB
was administered separately from rou-
tine vaccines, compared with 3211
(95% CI, 2949-3495) to 3332 (95% CI,
3120-3558) when administered to-
gether (TABLE 3).
The percentages of participants
achieving the threshold of response
for DTaP-HBV-IPV/Hib components
were noninferior in the accelerated
group compared with the control
group (lower limits of 95% CI of the
differences in these values being
greater than −10%), with the excep-
tion of pertactin (difference, −4%
[95% CI, −11% to 3%]). Noninferior-
ity was demonstrated for 6 of the 7
serotypes in the pneumococcal vac-
cine (serotypes 4, 9V, 14, 18C, 19F,
23F) but not for serotype 6B (differ-
ence, −5% [95% CI, −14% to 3%]),
because the lower limit of the differ-
ence in the percentage of participants
with antibody response greater or
equal to the prespecified cutoff level
was −14% (TABLE 4).
Reactogenicity and Safety
The numbers of participants experienc-
ing adverse reactions after immuniza-
tion are shown in the eTable available
at http://www.jama.com. Throughout
the study, fewer than 1% of all partici-
pants experienced severe erythema,
swelling, or induration at either of the
vaccination sites. However, 12% to 16%
in the concomitant and accelerated
groups, respectively, experienced se-
vere local pain after a dose of 4CMenB,
compared with 1% to 3% after doses of
DTaP-HBV-IPV/Hib or PCV7 in the con-
trol group.
Fever (38.0°C) after any vaccina-
tion was described in 80% (501/624) in
the concomitant group and 76% (243/
318) in the accelerated group, com-
pared with 51% (160/311) in control
group and 71% (447/627) in the inter-
calated group. For the intercalated
group there were twice as many immu-
nization days, and therefore more op-
portunity for fever to be experienced.
Rates of fever per 4CMenB dose are
shown in the eTable.
Table 1. Results of the Number of Infants Achieving Bactericidal Titers of 1:5 or Greater and the Percentages at Baseline and 1 Month After
the Third Vaccination (MITT Population and Multiple Imputation) and Vaccine Group Differencesa
Strain
% (95% CI)b
Concomitant Intercalated Accelerated Control
Vaccine Group Differences
Concomitant
Minus
Intercalated
Concomitant
Minus
Accelerated
Strain 44/76-SL
Baseline, No./totalc 47/525 38/531 16/272 16/248
MITTd 9.0 (6.7 to 11.7) 7.2 (5.1 to 10.0) 5.9 (3.4 to 9.4) 6.5 (3.7 to 10.3) 1.8 (−1.5 to 5.1) 3.1 (−0.6 to 6.8)
Multiple imputatione 8.7 (6.8 to 11.2) 6.80 (5.1 to 9.2) 6.8 (4.2 to 9.8) 6.5 (4.1 to 9.7) 1.9 (−1.2 to 4.9) 2.3 (−1.4 to 5.9)
Post third dose, No./totalc 521/525 528/531 270/272 11/248
MITTd 99.2 (98.1 to 99.8) 99.4 (98.4 to 99.9) 99.3 (97.4 to 99.9) 4.4 (2.2 to 7.8) −0.2 (−1.2 to 0.8) −0.03 (−1.3 to 1.2)
Multiple imputatione 98.9 (96.6 to 99.1) 98.8 (96.4 to 99.1) 98.4 (94.3 to 98.7) 10.5 (8.2 to 16.0) 0.1 (−1.4 to 1.6) 0.5 (−1.5 to 2.4)
Strain 5/99
Baseline, No./totalc 28/520 34/517 12/266 15/226
MITTd 5.4 (3.6 to 7.7) 6.6 (4.6 to 9.1) 4.5 (2.3 to 7.7) 6.6 (3.7 to 10.7) −1.2 (−4.1 to 1.7) 0.9 (−2.3 to 4.0)
Multiple imputatione 5.5 (4.0 to 7.7) 6.7 (4.9 to 8.9) 4.9 (3.0 to 7.8) 6.0 (3.7 to 9.2) −1.1 (−3.9 to 1.7) 0.7 (−2.4 to 3.8)
Post third dose, No./totalc 517/520 513/517 266/266 12/226
MITTd 99.4 (98.3 to 99.9) 99.2 (98.0 to 99.8) 100 (98.6 to 100) 5.3 (2.8 to 9.1) 0.2 (−0.8 to 1.2) −0.6 (−1.2 to 0.01)
Multiple imputatione 99.1 (96.8 to 99.3) 98.7 (96.2 to 98.9) 98.6 (94.6 to 98.9) 11.6 (9.0 to 17.2) 0.5 (−1.0 to 2.0) 0.4 (−1.6 to 2.3)
Strain NZ98/254
Baseline, No./totalc 18/528 5/526 6/268 2/250
MITTd 3.4 (2.0 to 5.3) 1.0 (0.3 to 2.2) 2.2 (0.8 to 4.8) 0.8 (0.1 to 2.9) 2.5 (0.7 to 4.2) 1.2 (−1.2 to 3.5)
Multiple imputatione 3.2 (1.9 to 5.0) 1.0 (0.4 to 2.3) 2.0 (0.8 to 4.3) 0.8 (0.1 to 2.8) 2.2 (0.5 to 3.8) 1.2 (−1.0 to 3.4)
Post third dose, No./totalc 417/528 453/526 219/268 11/250
MITTd 79.0 (75.2 to 82.4) 86.1 (82.9 to 89.0) 81.7 (76.6 to 86.2) 4.4 (2.2 to 7.7) −7.1 (−11.7 to −2.6) −2.7 (−8.5 to 3.05)
Multiple imputatione 79.0 (74.8 to 81.5) 86.1 (82.0 to 88.1) 79.1 (73.5 to 82.9) 9.7 (7.2 to 14.7) −7.0 (−11.6 to −2.44) −0.76 (−6.5 to 5.0)
Abbreviation: MITT, modified intention-to-treat.
aSee “Methods” for definition of groups.
bTwo-sided 95% CI calculated using Clopper-Pearson method.
cTotal numbers may differ from MITT population in Figure 1 because human complement serum bactericidal activities failed for individual strains.
dUnadjusted for center effect.
en=610 for the concomitant group; n=613 for the intercalated group; n=306 for the accelerated group; and n=309 for the routine group. See “Methods” for variables included in im-
putation model.
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Over the 8- to 10-month study, 166
serious adverse events were reported in
158 participants: 63 (10%) in the con-
comitant group, 57 (9%) in the interca-
lated group, 19 (6%) in the accelerated
group, and 19 (6%) in the control group.
Of these, 20 (9 concomitant, 7 interca-
lated, 3 accelerated, and 1 control) were
thought to be possibly related to
4CMenB or routine vaccinations.
Four possibly related serious adverse
events were seizures, 1 each following
routine vaccination in the intercalated
and accelerated groups, and 2 following
vaccination with 4CMenB in the inter-
calated group, 1 of the latter being a
febrile seizure 2 days after the second
4CMenB dose. Two hypotonic hypore-
Table 2. Geometric Mean Titers and Ratios (MITT Population), by Vaccination Groupa
Strain
GMT (95% CI) GMR (95% CI)
Concomitant Intercalated Accelerated Control
Concomitant
to Intercalated
Concomitant
to Accelerated
Strain 44/76-SLb n = 525 n = 531 n = 272 n = 248
Baseline
MITTc 1.51 (1.41-1.61) 1.38 (1.29-1.48) 1.34 (1.23-1.46) 1.27 (1.18-1.37) 1.09 (1.00-1.18) 1.12 (1.01-1.24)
Multiple imputationd 1.54 (1.44-1.65) 1.40 (1.32-1.50) 1.39 (1.28-1.51) 1.29 (1.20-1.38) 1.10 (1.01-1.19) 1.11 (1.01-1.22)
Post third dose
MITTc 83 (77-90) 110 (102-119) 82 (75-91) 1.26 (1.13-1.39) 0.75 (0.69-0.83) 1.01 (0.90-1.49
Multiple imputationd 85 (76-92) 106 (97-116) 80 (72-90) 1.71 (1.45-2.01) 0.80 (0.72-0.88) 1.05 (0.93-1.19)
Strain 5/99b n = 520 n = 517 n = 266 n = 226
Baseline
MITTc 1.29 (1.20-1.38) 1.28 (1.19-1.37) 1.20 (1.10-1.31) 1.24 (1.14-1.35) 1.01 (0.93-1.10) 1.07 (0.97-1.19)
Multiple imputationd 1.28 (2.00-1.37) 1.29 (1.21-1.38) 1.21 (1.11-1.32) 1.24 (1.15-1.33) 1.00 (0.92-1.08) 1.06 (0.97-1.17)
Post third dose
MITTc 520 (475-570) 669 (611-731) 323 (287-363) 1.43 (1.18-1.74) 0.78 (0.70-0.87) 1.61 (1.41-1.84)
Multiple imputationd 533 (475-598) 636 (572-709) 315 (274-361) 1.77 (1.66-2.73) 0.84 (0.74-0.95) 1.69 (1.44-1.99)
Strain NZ98/254b n = 528 n = 526 n = 268 n = 250
Baseline
MITTc 1.14 (1.09-1.19) 1.08 (1.04-1.13) 1.07 (1.01-1.13) 1.06 (1.03-1.10) 1.05 (0.90-1.11) 1.06 (1.00-1.14)
Multiple imputationd 1.13 (1.08-1.17) 1.08 (1.04-1.13) 1.06 (1.01-1.12) 1.06 (1.02-1.10) 1.04 (0.99-1.10) 1.06 (1.00-1.12)
Post third dose
MITTc 12 (10-13) 17 (15-19) 11 (9-12) 1.16 (1.06-1.25) 0.68 (0.59-0.80) 1.10 (0.91-1.32)
Multiple imputationd 12 (10-13) 16 (14-19) 10 (9-12) 1.40 (1.25-1.57) 0.71 (0.61-0.83) 1.15 (0.95-1.38)
Abbreviations: GMR, geometric mean ratio; GMT, geometric mean titer; MITT, modified intention-to-treat.
aSee “Methods” for definitions of groups.
bTotal numbers may differ from MITT population in Figure 1 because human complement serum bactericidal activities failed for individual strains.
cAdjusted for center effect.
dn=610 for the concomitant group; n=613 for the intercalated group; n=306 for the accelerated group; and n=309 for the routine group. See “Methods” for variables included in im-
putation model.
Table 3. Geometric Mean Bactericidal Antibody Concentrations Measured by ELISA Against Vaccine Antigen NHBA (per-Protocol Population
and Multiple Imputation Analysis)a
Group
ELISA Geometric Mean Antibody Concentration
Concomitant Intercalated Accelerated Control
U/mL
(95% CI)
Sample
Size,
No.
U/mL
(95% CI)
Sample
Size,
No.
U/mL
(95% CI)
Sample
Size,
No.
U/mL
(95% CI)
Sample
Size,
No.
Baseline
Per-protocol populationb 23 (21-24) 569 23 (22-24) 559 22 (21-24) 293 22 (21-23) 287
Multiple imputationc 23 (22-24) 615 23 (22-24) 615 23 (21-24) 307 22 (21-23) 307
Post third dose
Per-protocol populationb 3332 (3120-3558) 545 4342 (4067-4635) 557 3211 (2949-3495) 281 21 (20-21) 269
Multiple imputationc 3261 (2965-3587) 615 4039 (3697-4414) 609 3049 (2732-3402) 307 30 (26-36) 307
Ratio of post third dose to baseline
Per-protocol populationb 150 (136-165) 531 191 (174-210) 539 145 (128-164) 275 0.94 (0.89-0.99) 257
Multiple imputationc 143 (128-161) 615 175 (157-196) 609 135 (118-156) 307 1.39 (1.17-1.66) 307
Abbreviations: ELISA, enzyme-linked immunosorbent assay; NHBA, Neisseria heparin binding antigen.
aSee “Methods” for definitions of groups.
bAdjusted for center effect.
cn=610 for the concomitant group; n=613 for the intercalated group; n=306 for the accelerated group; and n=309 for the routine group. See “Methods” for variables included in im-
putation model.
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sponsiveepisodeswerereported,1within
12 hours of concomitant 4CMenB and
routine vaccines and 1 within 6 hours
after routine vaccines in the interca-
lated group. Two cases of Kawasaki dis-
ease were reported, 1 of which was con-
sidered possibly related to the study
vaccine by an independent expert panel.
Six children were observed in the hos-
pital because they had experienced fever
within 2 days after vaccination with
4CMenB. The remaining 5 possibly
related serious adverse events were asep-
tic meningitis, retinal dystrophy (be-
lieved to be congenital), transient syno-
vitis of the right hip, a transient hearing
loss noted by a parent, and transient
apnea after concomitant vaccination.
COMMENT
This study of more than 1800 infants
shows that when administered to-
gether with routine vaccines to healthy
infants, a primary immunization course
of 4CMenB is immunogenic against 3
reference strains expressing 1 of 3 vac-
cine antigens. Furthermore, 4CMenB
was immunogenic when administered
in a 2-, 3-, and 4-month schedule, an
important finding given the high rates
of MenB disease in the first 6 months
of life.15,16 These results suggest that
there can be some flexibility in the in-
corporation of 4CMenB into the vari-
ous immunization schedules used in
different countries.
Table 4. Immunogenicity of Routine Vaccines (DTaP-HBV-IPVHib and 7-Valent Pneumococcal) Given Concomitantly With or Without
4CMenB; Total Number and Percentage of Infants With Seroresponse Greater Than or Equal to a Prespecified Level and Geometric Mean
Antibody Concentrations (per-Protocol Population)a
Vaccine
Antigen
Threshold
of Response
No. of Participants With Positive Threshold/Total
No. Tested (% Participants Achieving
Threshold of Response) [95% CI]
Geometric Mean Antibody
Concentration/Titers
(95% CI)
Accelerated
Group Control Group
Difference in
Response, %
Accelerated
Group Control Group
Geometric Mean
Ratio
Diphtheria IgG0.10 IU/mL 238/238
(100) [98 to 100]
209/210
(100) [97 to 100]
0 (−1 to 3) 1.43 (1.30 to 1.57) 1.69 (1.53 to 1.87) 0.85 (0.75 to 0.95)
Tetanus IgG0.10 IU/mL 238/238
(100) [98 to 100]
210/210
(100) [98 to 100]
0 (−2 to 2) 1.91 (1.71 to 2.13) 2.00 (1.78 to 2.25) 0.95 (0.83 to 1.09)
Pertussis 4-fold increase
in IgG
FHA 182/238
(76) [71 to 82]
156/210
(74) [68 to 80]
2 (−6 to 10) 71 (65 to 79) 71 (64 to 79) 1.01 (0.89 to 1.14)
Pertactin 195/238
(82) [76 to 87]
181/210
(86) [81 to 91]
−4 (−11 to 3) 143 (125 to 164) 185 (160 to 214) 0.77 (0.65 to 0.91)
Pertussis
toxoid
204/238
(86) [81 to 90]
186/210
(89) [83 to 93]
−3 (−9 to 4) 35 (31 to 39) 37 (33 to 41) 0.94 (0.82 to 1.08)
Polio Titers1: 8
Type 1 174/175
(99) [97 to 100]
162/164
(99) [96 to 100]
1 (−2 to 4) 103 (83 to 128) 151 (120 to 189) 0.68 (0.53 to 0.89)
Type 2 162/174
(93) [88 to 96]
155/164
(95) [90 to 97]
−1 (−7 to 4) 62 (48 to 80) 89 (69 to 115) 0.70 (0.52 to 0.94)
Type 3 175/175
(100) [98 to 100]
159/164
(97) [93 to 99]
3 (1 to 7) 257 (201 to 329) 366 (284 to 472) 0.70 (0.52 to 0.94)
PRP-Hib IgG0.15 µg/mL 233/236
(99) [96 to 100]
204/209
(98) [95 to 99]
1 (−2 to 4) 2.39 (2.01 to 2.85) 2.51 (2.10 to 3.01) 0.95 (0.77 to 1.18)
Hepatitis type B
virus
IgG10 mIU/mL 199/206
(97) [93 to 99]
189/194
(97) [94 to 99]
−1 (−5 to 3) 243 (193 to 305) 319 (252 to 405) 0.76 (0.58 to 1.01)
Pneumococcal
serotype
IgG0.35 µg/mL
PnC 4 215/228
(94) [90 to 97]
192/203
(95) [91 to 97]
0 (−5 to 4) 1.97 (1.67 to 2.32) 2.08 (1.74 to 2.48) 0.95 (0.77 to 1.17)
PnC 6B 162/228
(71) [65 to 77]
155/203
(76) [70 to 82]
−5 (−14 to 3) 0.87 (0.68 to 1.09) 1.16 (0.91 to 1.50) 0.74 (0.55 to 1.00)
PnC 9V 224/228
(98) [96 to 100]
198/203
(98) [9 to 99]
1 (−2 to 4) 4.31 (3.71 to 5.00) 3.61 (3.08 to 4.24) 1.19 (0.99 to 1.44)
PnC 14 223/228
(98) [95 to 100]
192/203
(95) [91 to 97]
3 (0 to 8) 5.06 (4.28 to 6.00) 4.12 (3.44 to 4.93) 1.23 (0.99 to 1.53)
PnC 18C 223/228
(98) [95 to 100]
195/203
(96) [92 to 98]
2 (−2 to 6) 4.61 (3.91 to 5.42) 3.67 (3.09 to 4.37) 1.25 (1.02 to 1.54)
PnC 19F 224/228
(98) [96 to 100]
198/203
(98) [94 to 99]
1 (−2 to 4) 4.58 (3.89 to 5.39) 4.48 (3.77 to 5.34) 1.02 (0.83 to 1.26)
PnC 23F 212/228
(93) [89 to 96]
195/203
(96) [92 to 98]
−3 (−7 to 2) 2.38 (1.98 to 2.87) 2.68 (2.19 to 3.26) 0.89 (0.70 to 1.13)
Abbreviations: DTaP-HBV-IPV/Hib, combined diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B,Haemophilus influenzae type b; FHA, filamentous hemagglutinin; 4CMenB,
multicomponent serogroup B meningococcal vaccine; PRP-Hib, polyribosylribitol phosphate Haemophilus influenzae type b polysaccharide.
aSee “Methods” for definitions of groups.
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Immunogenicity of 4CMenB
When administered alone in the inter-
calated group rather than with rou-
tine vaccines, 4CMenB elicited higher
hSBA GMTs for all strains. Similarly, ad-
ministration of 4CMenB in a 2-, 4-, and
6-month schedule, rather than an ac-
celerated 2-, 3-, and 4-month sched-
ule, resulted in higher hSBA GMTs for
the 5/99 strain. However, immuniza-
tion schedules need to balance the ad-
vantages of optimal immunogenicity
and the practical need to minimize im-
munization visits and ensure early im-
munization. The clinical significance of
any reduction in hSBA GMTs is uncer-
tain, given that the proportion of par-
ticipants with an hSBA titer of 1:5 or
greater was at least 79% for all strains
in all 4CMenB recipients. Lower hSBA
GMTs may lead to shorter persistence
of bactericidal antibodies following pri-
mary immunization, as observed with
the serogroup C meningococcal vac-
cines17-19 and with the New Zealand
MenB vaccine (MeNZB).8,20 A fol-
low-up study of the same participants
assessing antibody persistence and the
response to a booster dose of 4CMenB
has been undertaken21 and will fur-
ther inform the relative benefits of the
different immunization schedules.
4CMenB immunogenicity in this
study is consistent with previous small
trials that found 4CMenB to be more
broadly immunogenic when given with
OMVs,8,9 possibly because of a syner-
gistic or enhancing effect of the OMV.
Furthermore, the OMV component of
4CMenB was used as a vaccine to con-
trol a clonal outbreak of MenB disease
in New Zealand, with an apparent ef-
fectiveness of 85% in children aged 6
months to 5 years22 after inducing very
similar hSBA titers against strain NZ98/
254.23 This provides confidence that the
levels of functional antibody induced
by this vaccine could indeed induce
protection against strains expressing the
vaccine antigens.
Immunogenicity
of Routine Vaccines
Concomitant 4CMenB impaired the im-
munogenicity of only 2 routine vac-
cine antigens: pertactin and pneumo-
coccal serotype 6B. This is unlikely to
be of clinical significance, because acel-
lular pertussis vaccines that lack pertac-
tin are known to be effective, and evi-
dence suggests that pneumococcal
disease resulting from the 6B serotype
is lower in countries that have imple-
mented vaccination with the PCV7 vac-
cine, although the putative response
threshold of IgG level of 0.35 µg/mL or
greater was achieved only by a rela-
tively low percentage of the immu-
nized population, possibly resulting
from both direct protection and herd
immunity.24
Breadth of Protection
Three strains expressing key vaccine an-
tigens were used for hSBA analysis,
demonstrating “proof of principle” im-
munogenicity of these antigens but al-
lowing only limited conclusions re-
garding cross-protection against other
naturally occurring strains. Also, data
from assays using strains genetically en-
gineered to express a range of fHbp1
subvariants25 and from early phase 2
studies8,9 suggest that genotypic analy-
sis of panels of invasive strains is not
sufficient to predict the likely breadth
of coverage of 4CMenB immunization
against invasive meningococcal dis-
ease in infants.
Further information regarding the
breadth of protection could be achieved
by testing against a more extended
panel of strains, as in previous 4CMenB
infant studies,8,9 but the number of
strains that can be tested by hSBA is lim-
ited by the volume of sera available from
infants, the limited supply of suitable
human complement, and the unsuit-
ability of many strains for hSBA.26 This,
combined with the evolutionary and
geographical variation in the target
MenB antigens, makes selection of
strain panels difficult.27 The meningo-
coccal antigen testing system28 using an
antigen-specific enzyme-linked immu-
nosorbent assay (evaluating both im-
munological cross-reactivity and anti-
gen expression) has an accuracy of 86%
in predicting the hSBA response and
might be suitable to assess the propor-
tion of MenB strains likely to be cov-
ered by the vaccine on a regional ba-
sis. Recently presented data suggest that
pooled sera from children immunized
with the 4CMenB vaccine would be bac-
tericidal against 78% (95% CI, 66% to
91%) of invasive strains in Europe29 and
against 76% (95% CI, 59% to 87%) of
such strains in Australia.30 However, the
ability of these laboratory assays to ac-
curately predict the effects of a MenB
vaccine—possibly also on non-MenB
pathogens expressing vaccine anti-
gens—is unknown and can only be
evaluated properly following imple-
mentation in a program with close sur-
veillance.
Reactogenicity
Outer membrane vesicle vaccines (eg,
MeNZB) have been administered to
more than 3 million children across
all age groups and are considered well
tolerated and safe.2 3 In trials of
MeNZB to control clonal outbreaks in
New Zealand, fever was the most pro-
nounced adverse reaction,31 with no
additional reactogenicity burden with
concomitant administration of MenB
and routine vaccines. In contrast, in
this study 4CMenB appeared to be
less reactogenic when administered
separately rather than together with
routine vaccines (although the study
made no formal statistical compari-
sons of reactogenicity rates between
groups). The majority of children in
this study became febrile after receiv-
ing their first and second dose of con-
comitant 4CMenB and routine vac-
cines, although only 1 child in our
study had a febrile convulsion (2 days
following 4CMenB administration).
There is therefore a need to compare
the risk profile of a relatively com-
mon, but transient, postimmunization
fever with the benefit of reducing the
risk of an uncommon, but potentially
fatal, meningococcal infection. This
must be carefully communicated
to parents in the event of routine
implementation if the possibility of
increased systemic reactogenicity is to
be an accepted component in the con-
trol of this serious disease. Rates and
SEROGROUP B MENINGOCOCCAL VACCINE IN INFANTS
580 JAMA, February 8, 2012—Vol 307, No. 6 ©2012 American Medical Association. All rights reserved.
Corrected on February 28, 2012
Downloaded From: http://jama.jamanetwork.com/ by a UNIEVERSITA DEGLI STUDI DI FIRENZE User  on 07/30/2012
magnitude of fever in this study are
comparable with those seen with
other pediatric vaccines, notably after
the second dose of ASO3B-adjuvanted
split virion H1N1 influenza vaccine
used in children aged 6 months to 5
years32 and whole-cell pertussis vac-
cine in 1 study,33 and were actually
lower than those observed in another
study of the pertussis vaccine.34
Limitations
The open-label design could poten-
tially bias reporting of adverse events
if parents were more alert to subjec-
tive reactions such as irritability if their
child received 4CMenB rather than rou-
tine vaccines. This would be less likely
to influence objective measures such as
temperature and extent of swelling or
erythema. The 3 strains selected for
hSBA analysis do not specifically evalu-
ate the immunogenicity of NHBA, be-
cause the only strain expressing NHBA
also contained porin protein A homolo-
gous to the OMV component. Concen-
trations of IgG specific to NHBA in-
creased following administration of
4CMenB; however, this was also ob-
served following administration of a
vaccine containing the recombinant
proteins without OMVs in early phase
2 studies. This increase in IgG GMCs
was not associated with an increase in
hSBA titers against NZ98/254,8,9 rais-
ing doubts about the bactericidal quali-
ties of these antibodies. A naturally oc-
curring strain allowing the assessment
of NHBA-induced bactericidal activity
has recently been identified35 and will
provide important additional informa-
tion regarding the immunogenicity of
this antigen.
CONCLUSIONS
In conclusion, 4CMenB was immuno-
genic, generally well tolerated, and
showed minimal interference with
routine vaccines in the first year of
life. The flexibility in schedule allows
it to be incorporated into a range of
country-specific immunization sched-
ules and for primary immunization to
be completed in early infancy. If
licensed, the decisions regarding vac-
cine introduction will require detailed
assessment of potential vaccine cover-
age at a regional level and monitoring
after implementation to determine the
accuracy of such predictions. Never-
theless, this vaccine could potentially
provide improved protection for
infants against meningococcal disease
beyond the protection provided by
currently licensed vaccines.
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